HOME ABOUT INVESTOR NEWS CALENDAR CONTACT We are builders. Strategy Management As the largest shareholder in Serendipity, management has a long-term commitment and perspective. We have an active role in the business operations and strategic management of our portfolio companies. Through continuous and iterative processes, each company is developed according to Serendipity’s principles. Investments Prior to new investments, we evaluate market potential, scalability, competitive advantage and differentiation, leadership, and the ability to deliver high margins over time. Neither management’s core competencies nor the commercialization process we apply are industry-specific. Therefore, Serendipity is not restricted to any particular industrial sector. Exit Serendipity is not exit-driven. However, divesting can be relevant if we believe a holding could be developed better under someone else’s management or if we see an opportunity to attain higher returns by investing in new companies. In general, we build to keep. As long as a holding generates satisfactory returns we do not see any reason to divest. We will periodically have companies in the portfolio that reach a maturity phase where an exit through trade sale or public listing is feasible. Such an exit will always be considered in relation to the potential returns we can obtain by continuing to develop the companies ourselves. COMPANY INFO INFO@SERENDIPITY.SE STUREPLAN 15 SE-111 45 STOCKHOLM SWEDEN PORTFOLIO COMPANIES DIAMORPH EPISURF MEDICAL ORGANOCLICK IRRAS PREMUNE SWECURE XBRANE BIOPHARMA VOFF SCIENCE Copyright All Rights Reserved © 2015

HOME ABOUT INVESTOR NEWS CALENDAR CONTACT About Serendipity Serendipity was founded in 2004 with the goal to identify, develop, and invest in technologies and trends with global market potential. We are company builders. As such, our focus and core competence lies in the processes of company development. Today, we have a diverse portfolio of listed and privately held companies within Cleantech, Medtech, Biotech, Advanced material, and Animal health. Serendipity’s management is also its largest shareholder, highly motivated and dedicated to its long-term development. Serendipity's Portfolio COMPANY INFO INFO@SERENDIPITY.SE STUREPLAN 15 SE-111 45 STOCKHOLM SWEDEN PORTFOLIO COMPANIES DIAMORPH EPISURF MEDICAL ORGANOCLICK IRRAS PREMUNE SWECURE XBRANE BIOPHARMA VOFF SCIENCE Copyright All Rights Reserved © 2015